• Vaccine Name: Cancer DNA Vaccine encoding Endoglin Boosted with Recombinant Endoglin Protein
• Target Pathogen: Cancer
• Target Disease: Cancer
• Vaccine Ontology ID: VO_0011367
• Type: DNA vaccine
• Status: Research
• Eng gene engineering:
  • Type: DNA Vaccine Construction and Recombinant Prot
  • Description:
  • Detailed Gene Information: Click Here.
• DNA vaccine plasmid:
  • DNA vaccine plasmid name:
  • DNA vaccine plasmid VO ID: VO_0000158
• Immunization Route: i.m. injection for DNA, s.c. for protein

Mouse Response

• Host Strain: BALB/c, C57BL/6
• Vaccination Protocol: The method of ppEDG DNA immunization; mice were injected i.m. in both quadriceps. A 1-ml insulin syringe was used for all injections and each single dose consisted of 100 μg that was diluted in normal saline of a total volume of 100 μl and split between both legs. The method of pEDG protein immunization; mice were injected s.c. and each single dose consisted of 10 μg that was also diluted in normal saline of a total volume of 100 μl. To investigate the protective anti-tumor effects mice at 6 to 8 weeks of age were randomly divided into the following 4 groups of 10 animals each. Group 1 (DP) mice were vaccinated with pEDG and ppEDG simultaneously once weekly for 4 continuous weeks. Group 2 (DD) mice were vaccinated with pEDG alone at the same time-points as in the group 1. Group 3 (PP) mice were vaccinated with ppEDG alone. Group 4 (NS) mice were injected with 100 μl normal saline. (Tan et al., 2007).
• Immune Response: CTL response against endoglin-positive HUVECs, but not against endoglin-negative tumor cells was found in the mice combined DNA with protein vaccination. In addition, combination of endoglin DNA and recombinant protein vaccination significantly induced IFN-gamma secreting cells (Tan et al., 2007).
• Challenge Protocol: One week after the last vaccination or saline injection all the experimental mice were subcutaneously injected with 2×10^6 live tumor cells (Tan et al., 2007).
• Efficacy: The results showed that combination of endoglin DNA and protein vaccines could enhance both protective and therapeutic anti-tumor efficacy in both colon carcinoma and Lewis lung carcinoma models. Significant inhibition of tumor angiogenesis was found in the tumor tissues (Tan et al., 2007).